Xeloda News and Research

RSS
Xeloda is a drug used to treat stage III colon cancer in patients who had surgery to remove the cancer. It is also used to treat metastatic breast cancer that has not improved after treatment with certain other anticancer drugs. Xeloda is being studied in the treatment of other types of cancer. It is taken up by cancer cells and breaks down into 5-fluorouracil, a substance that kills tumor cells. Xeloda is a type of antimetabolite. Also called capecitabine.
ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Astellas, AVEO enter development, commercialization agreement for tivozanib

Astellas, AVEO enter development, commercialization agreement for tivozanib

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Xeloda may reduce recurrence of faster growing breast cancers: Study

Xeloda may reduce recurrence of faster growing breast cancers: Study

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

Positive preliminary results from tivozanib-paclitaxel combination Phase 1b trial in metastatic breast cancer

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO to present data on tivozanib Phase 1b trial for breast cancer at SABCS Symposium

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

FDA approves Halaven therapy for metastatic late-stage breast cancer

FDA approves Halaven therapy for metastatic late-stage breast cancer

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Array BioPharma fiscal 2010 revenue increases to $53.9 million

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

Health Canada approves first targeted biological therapy to show survival benefit in stomach cancer

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

EMA grants Scientific Advice to Aeterna Zentaris for Phase 3 trial of anticancer compound perifosine

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Ph II data of perifosine + capecitabine in metastatic CRC to be presented at gastrointestinal cancer congress

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Aeterna Zentaris receives positive Scientific Advice from EMA for perifosine Phase 3 trial in colorectal cancer

Gastric cancer drug market to grow from $700M in 2009 to $1.5B in 2019

Gastric cancer drug market to grow from $700M in 2009 to $1.5B in 2019

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

ZIOPHARM Oncology announces guidance on palifosfamide Phase III trial in metastatic soft tissue sarcoma

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

Aeterna Zentaris reports final results on clinical activity of perifosine for metastatic colorectal cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.